Disease Progression

/Disease Progression

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]

To Debulk Or Not To Debulk, That Is The Question

You have been diagnosed with advanced or metastatic prostate cancer. It is a shock, you have cancer and your cancer has already spread outside of the prostate gland. Your doctor might have already told you that at this stage it is no longer curable, and technically it can be called terminal! That is a lot of stuff that has been just pushed on to your plate. Theoretically, this is correct, but for many of us, despite having this diagnosis, we will not die from the prostate cancer! Treatment today allows us to delay the cancer long enough that we will [...]

Prostate Cancer and Precision Medicine

One of the terms we hear in the world of cancer is precision medicine. In the area of prostate cancer what does this really mean? Precision medicine is a very broad term, but it can be better described as looking at an individual man’s genetic code and the genetic code of their tumors for the purpose of making treatment decisions. These genetic codes dictate both aggressiveness of the disease as well as the potential efficacy of a drug or treatment. Prostate cancer is a very heterogeneous disease; often each tumor contains multiple genetic structures. In addition, as the tumor spreads [...]

By | August 8th, 2016|Disease Progression, Drugs & Treatments, Uncategorized|0 Comments

18F-Fluciclovine PET/CT Superior to 11C-Choline PET/CT for the Detection of a Prostate Cancer Relapse

We have all been ever increasingly aware of the weakness of our scanning technologies when it comes to both diagnosing prostate cancer and its recurrence. Given that about 1/3 of all primary treatments for prostate cancer will fail and the cancer will return it is vital that we improve our ability to detect prostate cancer recurrences earlier. In recent years, there have been a few improved contrasts developed that have increased scanning sensitivity. Two competing contrasts are a new PET compound (anti-3-(18)F-FACBC or (18)F-fluciclovine) and (11)C-choline. Researchers set out to compare these two contrasts for their sensitivity to detect a [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー